Morgan Stanley Lifts Target On Valeant From $235 To $284 By: Benzinga via Benzinga July 27, 2015 at 09:02 AM EDT In a report published Monday, Morgan Stanley analyst David Risinger maintained an Overweight rating on Valeant Pharmaceuticals Intl. ... Read More >> Related Stocks: Valeant Pharmaceuticals International, Inc.